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APPT was constantly prolonged between 2-3 times control during the
treatment period.
Conclusion: Thrombolydc therapy with I’I-R4 in Patients with aCUte mY-
ocerdial infarction Is associated with an increase in thrombin generation
which ia not suppressed by therapeutic doses of the specific thrombin in-
hibitor r-hirudin, while circulating thrombin seems to be effectively inhibited
by r-hirudin.
EmEl Successful Revascularizetion by DirectCoronary Angloplasty Reducad the Expression
of Polym-orphon-uclearLeukocyte Adhesion
Molacules of Patients with Acute Myocardial
Infarction
Y. Sakai, T. Inoue, H. Hatano, K. Hoshi, 1.Yaguchi, K. Takayanagi,
T. Hayashi, S. Morooka. Depaflrnerrt of Carcfio@ry.Koehig8ya Hospital,
L70kkyoUn/vers/fySck3010fMedicine, S8iIerna, Japan
In acute myocardial infarction, it was well known that the early revaacular-
ization aavad the ischemic myocardium but caused the reperfusion injuriea.
Direct percutaneous trensluminal coronary angioplaefy (pTCA) is the most
desirable therapy to save the iechemic myocardium, but it is unknown why
direct PTCA is better than intracoronaty thrombolysis (lCT) to acute my-
ocardlal infarction. So we atudiad the difference in inflammatory activation
between direct PTCAand ICT using leukocyte adhesion molecules including
LFA-I (CDlldCD18), Mac-1 (CDIIWCD18), L-selwtin (CD62L) and sia-
Iyl Lewisx (SLX) in acute myocardial infarction. Twenty patients with acute
myocerdial infarction were treated with successful revascularizstion within 6
hours after the onset. In ICT group (12 patients), the levels of CD18, CDlla,
CDllb, CD62Land SLX increased immediately after revascularization. In di-
rect PTCA group, the levels were significantly lower than those of ICT group
(CD18: 47 + 6 VS 149 + 23, P <0.05, CDllb: 658 +90 VS 901 + 96, P <
0.05, CD62L: 32 + 7 vs 50 l 15, P < 0.05). Especially, 8 patients of ICT
group hadventricular arrhythmia at rsparfusion and showad a significant cor-
relation with CDllb level. In conclusion, direct PTCA reducedthe expression
of polymorphonuclear leukocyte adhesion molecules at the revascularization
of acute myocardial infarction and dacreaaad tha reperfusion injuries more
than intrscoronary thrombolysis in acute myocardial infarction.
m1079113 Early ACE Inhibitor Therapy Enhances theBenefits of Late Coronary Artery Reparfusion on
Infarct Expansion
P.Sahgal, E.J. Brown, Jr., L. Tkaczevski, R. Mir, N. Muia, Jr., LA. Alhaddad.
Nassau Counfyfdedicai Center, East Meadow, NY USA, Bronx Lebanon
Hospital Centec Bronx, NY USA
Reperfusion 8 hours after experimental rat myocardial infarction will limit
infarct expenaion. Our purpose was to examine the effects and mechanism
of earfy ACE Inhibitor therapy on infarct expanaion when combined with late
raperfusion. Rate underwent 8 houre of coronary artery occlusion followed
by permanent raperfusion. The enalapril group raceivad enalapril (0.1 mg/Kg
IV) 1 hour after coronary occlusion followed by enalapril (1.0 + 2 mg/Kg)
daily in drinking water. A control group received placebo. Two weeka after
myooardiel infarction, the hearts wera arrestad and fixad at a constant end
diaatolic pressure, then sectioned for morphometric analysis. Hearf sections
were stained with H&E for histological analysis. Viable ialets of myocytes
within the scar (Viable Myccytes) were quantitatad and call diameters were
measured. Results follow as mean + SEM.
Enalapril(n = 10) Control(n =9) P
ExpansionIndex 1.17 * 0,12 1.57 i 0.12 <0.05
infarctThickneaa(mm) 0.93 * 0.07 0.76 + 0.04 <0.05
Vlsble Myccytes (“A) 11.6 + 3.70 9.40 + 2.50 N.S.
Viable MyocyteS-DlametSr(pm) 11,1 * 1.50 8.80 i 1.30 <0.01
Non InfarctMyocytea-Diamster (pm) 11.3 l2.2 8.40 + 1.80 <0.01
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Sulfonylurea Drug USCIs Associated With
Increased Early Mortality During Diract Coronary
Anglopleety For Acute tiyocardisl Infarction -
Among Diabetic Patients
K.N. Garratt, N. Hassinger, D.E. Grill, A. Terzic, S.S. Srivatee, D.R. Holmes,
Jr.. Mayo C/inic, RochesteCMN, USA
Whether sulfonylurea therapy, which blocks cyfoprotective ATP-sensitive
potassium channels, impedes cardioprotective mechanisms during ischemic
events remains controversial. Therefore, we reviewad dare for 188 diabetic
pts with acute myocardial infarction treated with direct angioplasty at Mayo
Clinic to determine the effect of sulfonylurea drug use on clinical outcome.
There wera 115 (81%) males, mean + SD age 65 + 12 yre; 39 (21%)
presented with heart failure, 67 (36%) were taking an oral sulfonylurea hypo-
glycemicdrug, Angioplasfy was successful (Iuminal improvement > 40%, no
death, new infarction of bypass surgety) in 148 (79%) pts. Logistic modeling
[OR = odds ratio, Cl = upper and lower 95% confidence intervals] identified
sulfonylurea drug use (OR= 2.5, Cl = 1.1-5.6, P =0.03) in addition to lettven-
tricularejacfion fraction < 40% (OR =7, Cl = 1.6-31.2, P= O.01),prior bypass
surgery (OR = 3.6, Cl = 1.3-9.9, P = 0.01), age (OR= 1.05, Cl = 1.006-1.09,
P = 0.02), and heati failure (OR= 2.3, Cl= 1-5.4, P = 0.06) as correlates of
increased in-hospital mortality. Elevated glycosylated hemoglobin, gender,
hypertension, and hyperoholesteroiemia were not associated with Increased
mottslify risk. Survivors were followed for a mean + SD of 3.7 + 2.4 yra. Cox
proportional hazards modeling found heart failure (relative riak (RR) = 3.5,
P = 0.0006), female gender (RR= 0.5, P = 0.03), prior bypass surgery (RR
= 3, P = 0.03) and hypertension (RR = 0.4, P = 0.04) but not aulfonylurea
drug use to be associated with late morfalify. ConchAons: Among diabetic
pfs undergoing direct angioplasty for acute myocardial Infarction, oral sul-
fonylurea drug use appears to confer an increased risk of early mortality
roughly equivalent to that conferred by heari failure. Late survival was not
influenced by sulfonylurea therapy. Interactions between sulfonylurea drugs
and ATP-sensitive potassium channels participating in myocardial protection
to prolonged ischemia are postulated to contribute to an increesad earty
mortality risk.
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Thrombolysls as a Predictor for Early and Lsta
Reocclusion
T.K. Nordt, M. Moaer,K. Peter, B. Kohler, C. Bode. Med. Un/versiMtsk/inik
Heide/Lrerg,Germany
Reocclusion after initially auccesaful thrombolysia is detrimental to the long-
tanmoutmme after acute myocardial infarction (AMI). Besides angiogrsphic
criteria, no clinical variables could be identified as predictor for reocclusion.
To evaluate hemoeteaeologic criteria as potential riak determinants 31 pa-
tients with AMI were monitored by thrombin antithrombin complexea (TAT,
representing plasmatic hemoatasis), platelet aggregation (PA, representing
callular hemostesis), and plasminOgenactivator inhibitor type 1 (PAI-1, rep-
resenting endogenous fibrinolysis) at O, 1, 2, and 12 h after initiation of
thrombolysis as well as at discharge. Raocclusion was defined as rein-
farcfion or angiographioelly confirmed ailent reocclusion and occurred in 5
patienta within 10 d and in 8 patients within 1 y. TAT levels were lower in
patients with raocclusion veraus those without (9.9 + 2.5 va. 22.9 + 4.4
n~ml at 2 h, 6.5 + 1.4 vs. 11.2 + 1.3 ngfml at 12 h, meane + SEM, p <
0.05). The concentration and activity of PAI-1 did not differ in both patient
groupe. However, both alope and maximum of PA (induced by 2 #M ADP)
were augmented with reoccluaion [slope: 39.4 + 0.8 vs. 32.5 + 1.5 at 2 h
(p < 0.001), 42.6 + 1.2 va. 36.6 + 1.7 at 12 h (p -= 0.01)]. Results were
independent of the thrombolytic agent uaad (alteplase or reteplase). A PA
slope at 2 h higher than the average slope at O h (37.0) could be identified
as beat predictor for earfy (within 10 d, p <0.01, sensitivity 100%, specificity
69%) and late reocclusion (within 1y, p c 0.01, 66% and 74%, respectively).
Thua, increased PA under coronary thrombolysis appears to be aaeociated
with early and late raocclusion. Thia marker could be useful in identifying
patients who may profit from more aggressive interventional or antiplatelet
strategies.
In conclusion, earty ACE Inhibitor therapy enhances the benefits of late
coronary reperfusion on infarct expansion. These benefits maybe related to
hyperfrophy of viable myocytes within the infarcted as well as non-infarcted
zone.
